Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study

BACKGROUND AND AIMS: The benefits of the PCSK9 inhibitors, alirocumab and evolocumab, in lowering LDL-cholesterol and preventing major adverse cardiac events (MACE) have been demonstrated in pivotal clinical trials. However, few studies of routine clinical practice have been conducted to analyse and...

Descripción completa

Detalles Bibliográficos
Autores principales: Blanco-Ruiz, Marina, Amaya-Pascasio, Laura, de Torres Chacón, Reyes, Álvarez Soria, María Josefa, Arjona-Padillo, Antonio, Carrillo Bailén, María Magdalena, Milán Pinilla, Rodrigo, Pérez Ortega, Irene, Sánchez Rodríguez, Belén, Andrade Zumárraga, Luis, Valverde Moyano, Roberto, Payán Ortiz, Manuel, Castillo Fernández, Alba María, Del Toro Pérez, Cristina, González Bustos, Pablo, Agüera Morales, Eduardo, Sánchez López, Purificación, Hidalgo Martín, Beatriz, Roa Chamorro, Ricardo, Fernández Pérez, Javier, Mejías Olmedo, María Victoria, Martínez-Sánchez, Patricia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833257/
https://www.ncbi.nlm.nih.gov/pubmed/36643997
http://dx.doi.org/10.1016/j.athplu.2021.08.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833257/
https://www.ncbi.nlm.nih.gov/pubmed/36643997
http://dx.doi.org/10.1016/j.athplu.2021.08.009

Ejemplares similares